Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03597282
Title A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Neon Therapeutics, Inc.



Ipilimumab + Nivolumab

APX005M + Nivolumab

Ipilimumab + NEO-PV-01 + Nivolumab + Poly ICLC

APX005M + NEO-PV-01 + Nivolumab + Poly ICLC

Nivolumab + Poly ICLC

NEO-PV-01 + Nivolumab + Poly ICLC

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.